Invitrogen Corporation IVGN - U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen
U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen
City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/09/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). U.S. BioDefense, Inc. (OTC BB: UBDE) announced recently it has received a $200,000 commitment from Equity Solutions, Inc. for corporate development and identifying merger and acquisition candidates. The funding commitment entails Equity Solutions to assist with shareholder relations, introduction to other funding sources, building a management team and strategic alliances. Genta Incorporated (Nasdaq: GNTA) recently announced financial results for the second quarter 2006. "The Company continues to make solid progress in our Clinical, Regulatory, Manufacturing, and Sales and Marketing activities as we prepare for the potential U.S. launch of Genasense," commented Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta.
Invitrogen Corp. (Nasdaq:IVGN), an advanced lab research equipment and services company, was upgraded by a Bank of America analyst Tuesday, who cited its cheap valuation as well as potential benefits from its research and development investments. In a client note, analyst Frank Pinkerton upgraded the Carlsbad, Calif.-based company to "Buy" from "Neutral," citing valuation and new market opportunities, specifically in the molecular diagnostic and biodefense markets. Martek Biosciences (Nasdaq:MATK) said Tuesday it will supply nutritional oils for infant formula manufactured by Hain Celestial Group Inc., an organic food company, and two firms are in ongoing talks to use Martek's fatty acids in other food and beverage products. Hain Celestial recently unveiled a new infant formula marketed under the Earth's Best brand, a leading organic baby and toddler food manufacturer.
City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/09/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). U.S. BioDefense, Inc. (OTC BB: UBDE) announced recently it has received a $200,000 commitment from Equity Solutions, Inc. for corporate development and identifying merger and acquisition candidates. The funding commitment entails Equity Solutions to assist with shareholder relations, introduction to other funding sources, building a management team and strategic alliances. Genta Incorporated (Nasdaq: GNTA) recently announced financial results for the second quarter 2006. "The Company continues to make solid progress in our Clinical, Regulatory, Manufacturing, and Sales and Marketing activities as we prepare for the potential U.S. launch of Genasense," commented Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta.
Invitrogen Corp. (Nasdaq:IVGN), an advanced lab research equipment and services company, was upgraded by a Bank of America analyst Tuesday, who cited its cheap valuation as well as potential benefits from its research and development investments. In a client note, analyst Frank Pinkerton upgraded the Carlsbad, Calif.-based company to "Buy" from "Neutral," citing valuation and new market opportunities, specifically in the molecular diagnostic and biodefense markets. Martek Biosciences (Nasdaq:MATK) said Tuesday it will supply nutritional oils for infant formula manufactured by Hain Celestial Group Inc., an organic food company, and two firms are in ongoing talks to use Martek's fatty acids in other food and beverage products. Hain Celestial recently unveiled a new infant formula marketed under the Earth's Best brand, a leading organic baby and toddler food manufacturer.
posted by Famous Quotations - Invitrogen Corporation IVGN - U.S. BioDefense Receives $200,000 Commitment from Equity Solutions and BofA Analyst Upgrades Invitrogen
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home